Oxidative stress: A new risk factor for thyroid cancer

Endocrine-Related Cancer

Volumn 19, Issue 1, 2012, Pages

  Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REACTIVE OXYGEN METABOLITE; THYROTROPIN; THYROTROPIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; ANTIOXIDANT;

CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; NOTE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; THYROID CANCER; BLOOD; FEMALE; MALE; METABOLISM; THYROID DISEASE; THYROID TUMOR;

ANTIOXIDANTS; FEMALE; HUMANS; MALE; REACTIVE OXYGEN SPECIES; THYROID DISEASES; THYROID NEOPLASMS;

EID: 84860350025     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0360     Document Type: Note

References (35)

1. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka M, Shiojima I, Hiroi Y & Yazaki Y 1997 Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. Journal of Clinical Investigation 100 1813-1821. (doi:10.1172/JCI119709)
2. Akinci M, Kosova F, Cetin B, Sepici A, Altan N, Aslan S & Cetin A 2008 Oxidant/antioxidant balance in patients with thyroid cancer. Acta Cirúrgica Brasileira 23 551-554. (doi:10.1590/S0102-86502008000600013)
3. Andryskowski G & Owczarek T 2007 The evaluation of selected oxidative stress parameters in patients with hyperthyroidism. Polish Archives of Internal Medicine 117 285-289. (Pubitemid 47605689)
4. Aslan M, Cosar N, Celik H, Aksoy N, Dulger AC, Begenik H, Soyoral YU, Kucukoglu ME & Selek S 2011 Evaluation of oxidative status in patients with hyperthyroidism. Endocrine 40 285-289. (doi:10.1007/s12020-011-9472-3)
5. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC & Franklyn JA 2006 Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. Journal of Clinical Endocrinology and Metabolism 91 4295-4301. (doi:10.1210/jc.2006-0527)
6. Commoner B, Townsend J & Pake GE 1954 Free radicals in biological materials. Nature 174 689-691. (doi:10.1038/174689a0)
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 11 1167-1214.
8. 2-generating system modulates protein iodination and the activity of the pentose phosphate pathway in dog thyroid. Endocrinology 128 779-785. (doi:10.1210/endo-128-2-779)
9. Dröge W 2002 Free radicals in the physiological control of cell function. Physiological Reviews 82 47-95. (Pubitemid 34654215)
10. Durackova Z 2010 Some current insights into oxidative stress. Physiological Research 59 459-469.
11. Erdamar H, Demirci H, Yaman H, Erbil MK, Yakar T, Sancak B, Elbeg S, Biberoǧlu G & Yetkin I 2008 The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. Clinical Chemistry and Laboratory Medicine 46 1004-1010. (doi:10.1515/CCLM.2008.183)
12. Fukuyo Y, Inoue M, Nakajima T, Higashikubo R, Horikoshi NT, Hunt C, Usheva A, Freeman ML & Horikoshi N 2008 Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. Cancer Research 68 6324-6330. (doi:10.1158/0008-5472.CAN-07-6602)
13. Gerschman R, Gilbert DL, Nye SW, Dwyer P & Fenn WO 1954 Oxygen poisoning and X-irradiation - a mechanism in common. Science 119 623-626. (doi:10.1126/science.119.3097.623)
14. 2. Role in cell survival following oxidant injury. Journal of Biological Chemistry 271 4138-4142. (doi:10.1074/jbc.271.7.3604)
15. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC & Chen H 2009 Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clinical Endocrinology 71 434-439. (doi:10.1111/j.1365-2265.2008.03489.x)
16. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA & Fagin JA 2011 Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30 3153-3162. (doi:10.1038/onc.2011.44)
17. Lassoued S, Mseddi M, Mnif F, Abid M, Guermazi F, Masmoudi H, El Feki A & Attia H 2010 A comparative study of the oxidative profile in Graves' disease, Hashimoto's thyroiditis, and papillary thyroid cancer. Biological Trace Element Research 138 107-115. (doi:10.1007/s12011-010-8625-1)
18. Liu D & Xing M 2008 Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid 18 853-864. (doi:10.1089/thy.2007.0357)
19. Lu H, Ouyang W & Huang C 2006 Inflammation, a key event in cancer development. Molecular Cancer Research 4 221-233. (doi:10.1158/1541-7786.MCR-05- 0261)
20. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E et al. 2010 B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. PNAS 107 10649-10654. (doi:10.1073/pnas.1004934107)
21. Nucera C, Lawler J & Parangi S 2011 BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Research 71 2417-2422. (doi:10.1158/0008-5472.CAN-10-3844)
22. Pacifico F & Leonardi A 2010 Role of NF-kappaB in thyroid cancer. Molecular and Cellular Endocrinology 321 29-35. (doi:10.1016/j.mce.2009.10.010)
23. Poli G, Leonarduzzi G, Biasi F & Chiarpotto E 2004 Oxidative stress and cell signalling. Current Medicinal Chemistry 11 1163-1182. (Pubitemid 38585060)
24. Rao GN & Berk BC 1992 Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circulation Research 70 593-599.
25. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M & Santisteban P 2009 The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Research 69 8317-8325. (doi:10.1158/0008-5472.CAN-09-1248)
26. Senthil N & Manoharan S 2004 Lipid peroxidation and antioxidants status in patients with papillary thyroid carcinoma in India. Asia Pacific Journal of Clinical Nutrition 13 391-395. (Pubitemid 40064071)
27. Spencer JPE 2005 Interactions of flavonoids and their metabolites with cell signaling cascades. In Nutrigenomics, pp 353-377. Eds G Rimbach, J Fuchs & L Packer. Boca Raton: Taylor & Francis Publishing.
28. Stayner LT, Dankovic DA & Lemen RA 1996 Occupational exposure to chrysotile asbestos and cancer risk: A review of the amphibole hypothesis. American Journal of Public Health 86 179-186. (doi:10.2105/AJPH.86.2.179)
29. Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E & Tutuncu NB 2009 Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clinical Endocrinology 70 469-474. (doi:10.1111/j.1365-2265.2008.03348.x)
30. Valko M, Morris H, Mazur M, Rapta P & Bilton RF 2001 Oxygen free radical generating mechanisms in the colon: do the semiquinones of vitamin K play a role in the etiology of colon cancer? Biochimica et Biophysica Acta 1527 161-166. (doi:10.1016/S0304-4165(01)00163-5)
31. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M & Telser J 2007 Free radicals and antioxidants in normal physiological functions and human disease. International Journal of Biochemistry & Cell Biology 39 44-84. (doi:10.1016/j.biocel.2006.07.001)
32. Wang D, Feng J, Zeng P, Yang Y, Luo J & Yang Y 2011 Total oxidant/antioxidant status in sera of patients with thyroid cancers. Endocrine-Related Cancer 18 773-782. (doi:10.1530/ERC-11-0230)
33. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762. (doi:10.1210/er.2007-0007)
34. Xing M 2010 Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20 697-706. (doi:10.1089/thy.2010.1646)
35. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6379. (doi:10.1210/jc.2005-0987)